MDT Quote, Financials, Valuation and Earnings

Electromed has a net margin of 15.11% compared to Medtronic PLC's net margin of 10.05%. Medtronic PLC's return on equity of 8.54% beat Electromed's return on equity of 15.62%.

Medtronic PLC has a consensus price target of $96.00, signalling upside risk potential of 17.74%. On the other hand Electromed has an analysts' consensus of -- which suggests that it could grow by 11.56%. Given that Medtronic PLC has higher upside potential than Electromed, analysts believe Medtronic PLC is more attractive than Electromed.

Medtronic PLC has a beta of 0.820, which suggesting that the stock is 17.999% less volatile than S&P 500. In comparison Electromed has a beta of 0.285, suggesting its less volatile than the S&P 500 by 71.506%.

Medtronic PLC has a quarterly dividend of $0.70 per share corresponding to a yield of 3.41%. Electromed offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Medtronic PLC pays 99.73% of its earnings as a dividend. Electromed pays out -- of its earnings as a dividend. Medtronic PLC's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Medtronic PLC quarterly revenues are $8.4B, which are larger than Electromed quarterly revenues of $14.7M. Medtronic PLC's net income of $1.3B is higher than Electromed's net income of $1.5M. Notably, Medtronic PLC's price-to-earnings ratio is 24.94x while Electromed's PE ratio is 41.08x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Medtronic PLC is 3.24x versus 4.62x for Electromed. Usually stocks with elevated PS ratios are considered overvalued.

Inspire Medical Systems has a net margin of 15.11% compared to Medtronic PLC's net margin of 9.1%. Medtronic PLC's return on equity of 8.54% beat Inspire Medical Systems's return on equity of 5.44%.

Medtronic PLC has a consensus price target of $96.00, signalling upside risk potential of 17.74%. On the other hand Inspire Medical Systems has an analysts' consensus of $239.60 which suggests that it could grow by 28.62%. Given that Inspire Medical Systems has higher upside potential than Medtronic PLC, analysts believe Inspire Medical Systems is more attractive than Medtronic PLC.

Medtronic PLC has a beta of 0.820, which suggesting that the stock is 17.999% less volatile than S&P 500. In comparison Inspire Medical Systems has a beta of 1.313, suggesting its more volatile than the S&P 500 by 31.289%.

Medtronic PLC has a quarterly dividend of $0.70 per share corresponding to a yield of 3.41%. Inspire Medical Systems offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Medtronic PLC pays 99.73% of its earnings as a dividend. Inspire Medical Systems pays out -- of its earnings as a dividend. Medtronic PLC's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Medtronic PLC quarterly revenues are $8.4B, which are larger than Inspire Medical Systems quarterly revenues of $203.2M. Medtronic PLC's net income of $1.3B is higher than Inspire Medical Systems's net income of $18.5M. Notably, Medtronic PLC's price-to-earnings ratio is 24.94x while Inspire Medical Systems's PE ratio is 174.10x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Medtronic PLC is 3.24x versus 7.41x for Inspire Medical Systems. Usually stocks with elevated PS ratios are considered overvalued.

Inari Medical has a net margin of 15.11% compared to Medtronic PLC's net margin of -11.97%. Medtronic PLC's return on equity of 8.54% beat Inari Medical's return on equity of -17.68%.

Medtronic PLC has a consensus price target of $96.00, signalling upside risk potential of 17.74%. On the other hand Inari Medical has an analysts' consensus of $66.46 which suggests that it could grow by 23.88%. Given that Inari Medical has higher upside potential than Medtronic PLC, analysts believe Inari Medical is more attractive than Medtronic PLC.

Medtronic PLC has a beta of 0.820, which suggesting that the stock is 17.999% less volatile than S&P 500. In comparison Inari Medical has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Medtronic PLC has a quarterly dividend of $0.70 per share corresponding to a yield of 3.41%. Inari Medical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Medtronic PLC pays 99.73% of its earnings as a dividend. Inari Medical pays out -- of its earnings as a dividend. Medtronic PLC's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Medtronic PLC quarterly revenues are $8.4B, which are larger than Inari Medical quarterly revenues of $153.4M. Medtronic PLC's net income of $1.3B is higher than Inari Medical's net income of -$18.4M. Notably, Medtronic PLC's price-to-earnings ratio is 24.94x while Inari Medical's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Medtronic PLC is 3.24x versus 5.42x for Inari Medical. Usually stocks with elevated PS ratios are considered overvalued.

Nevro has a net margin of 15.11% compared to Medtronic PLC's net margin of -15.83%. Medtronic PLC's return on equity of 8.54% beat Nevro's return on equity of -24.66%.

Medtronic PLC has a consensus price target of $96.00, signalling upside risk potential of 17.74%. On the other hand Nevro has an analysts' consensus of $5.68 which suggests that it could grow by 43.16%. Given that Nevro has higher upside potential than Medtronic PLC, analysts believe Nevro is more attractive than Medtronic PLC.

Medtronic PLC has a beta of 0.820, which suggesting that the stock is 17.999% less volatile than S&P 500. In comparison Nevro has a beta of 0.841, suggesting its less volatile than the S&P 500 by 15.88%.

Medtronic PLC has a quarterly dividend of $0.70 per share corresponding to a yield of 3.41%. Nevro offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Medtronic PLC pays 99.73% of its earnings as a dividend. Nevro pays out -- of its earnings as a dividend. Medtronic PLC's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Medtronic PLC quarterly revenues are $8.4B, which are larger than Nevro quarterly revenues of $96.9M. Medtronic PLC's net income of $1.3B is higher than Nevro's net income of -$15.3M. Notably, Medtronic PLC's price-to-earnings ratio is 24.94x while Nevro's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Medtronic PLC is 3.24x versus 0.35x for Nevro. Usually stocks with elevated PS ratios are considered overvalued.